128 results
10-Q
2024 Q1
EX-10.1
SKYE
Skye Bioscience Inc
Quarterly report
10 May 24
4:02pm
8-K
EX-10.1
SKYE
Skye Bioscience Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
EX-10.2
SKYE
Skye Bioscience Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
EX-10.1
SKYE
Skye Bioscience Inc
29 Jan 24
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
8:02am
8-K
EX-10.2
SKYE
Skye Bioscience Inc
29 Jan 24
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
8:02am
8-K
EX-10.1
t7of44jloi i1z
5 Dec 23
Entry into a Material Definitive Agreement
5:04pm
8-K
EX-10.2
bc37o4
5 Dec 23
Entry into a Material Definitive Agreement
5:04pm
8-K
EX-10.1
od7cruigiy
3 Oct 23
Departure of Directors or Certain Officers
4:34pm
8-K
EX-10.3
0h62ryrg4x
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.1
b6jm4qrbgjoqdc jjj
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.4
e61oz0a10e
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.2
j4did97ergqfo5 9620
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.1
30btc54v
23 Feb 23
Entry into a Material Definitive Agreement
5:18pm
8-K
EX-10.1
4ow3 ciyy389o5h8r
15 Feb 23
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
4:26pm
8-K
EX-10.1
483jek m719xcq4u
26 Jan 23
Entry into a Material Definitive Agreement
9:22pm
8-K
EX-10.1
gm2l95kvqrz3
6 Jan 23
Entry into a Material Definitive Agreement
4:57pm
8-K
EX-10.1
aeb4qey54sojq11bp
16 Dec 22
Entry into a Material Definitive Agreement
6:40pm